A therapeutic antibody targeting osteoprotegerin attenuates severe experimental pulmonary arterial hypertension
Main Authors: | Arnold, ND, Pickworth, JA, West, LE, Dawson, S, Carvalho, JA, Casbolt, H, Braithwaite, AT, Iremonger, J, Renshall, L, Germaschewski, V, McCourt, M, Bland-Ward, P, Kowash, H, Hameed, AG, Rothman, AMK, Frid, MG, Thompson, AA, Evans, HR, Southwood, M, Morrell, NW, Crossman, DC, Whyte, MKB, Stenmark, KR, Newman, CM, Kiely, DG |
---|---|
Format: | Journal article |
Language: | English |
Published: |
Nature Research
2019
|
Similar Items
-
Differential IL-1 signaling induced by BMPR2 deficiency drives pulmonary vascular remodeling
by: Josephine Pickworth, et al.
Published: (2017-09-01) -
Effect of osteoprotegerin and osteoprotegerin ligand on osteoclast formation by arthroplasty membrane derived macrophages.
by: Itonaga, I, et al.
Published: (2000) -
Selective improvement of pulmonary arterial hypertension with a dual ET/ET receptors antagonist in the apolipoprotein E model of PAH and atherosclerosis
by: Lewis Renshall, et al.
Published: (2018-01-01) -
Role of osteoprotegerin (OPG) in cancer.
by: Holen, I, et al.
Published: (2006) -
Osteoprotegerin and the development of myeloma bone disease
by: Croucher, P, et al.
Published: (2004)